|
Name |
[(4S)-11-(3,5-dihydroxyphenyl)undecan-4-yl] 2-[(8S)-8-acetyloxyundecyl]-4,6-dihydroxybenzoate
|
Molecular Formula | C37H56O8 | |
IUPAC Name* |
[(4S)-11-(3,5-dihydroxyphenyl)undecan-4-yl] 2-[(8S)-8-acetyloxyundecyl]-4,6-dihydroxybenzoate
|
|
SMILES |
CCC[C@@H](CCCCCCCC1=C(C(=CC(=C1)O)O)C(=O)O[C@@H](CCC)CCCCCCCC2=CC(=CC(=C2)O)O)OC(=O)C
|
|
InChI |
InChI=1S/C37H56O8/c1-4-16-33(44-27(3)38)20-14-11-7-9-13-19-29-24-32(41)26-35(42)36(29)37(43)45-34(17-5-2)21-15-10-6-8-12-18-28-22-30(39)25-31(40)23-28/h22-26,33-34,39-42H,4-21H2,1-3H3/t33-,34-/m0/s1
|
|
InChIKey |
LCCCZIASPPCLCU-HEVIKAOCSA-N
|
|
Synonyms |
Integracin A; 224186-03-2
|
|
CAS | NA | |
PubChem CID | 124354153 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 628.8 | ALogp: | 11.4 |
HBD: | 4 | HBA: | 8 |
Rotatable Bonds: | 25 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 134.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 45 | QED Weighted: | 0.062 |
Caco-2 Permeability: | -5.154 | MDCK Permeability: | 0.00001830 |
Pgp-inhibitor: | 0.075 | Pgp-substrate: | 0.018 |
Human Intestinal Absorption (HIA): | 0.009 | 20% Bioavailability (F20%): | 1 |
30% Bioavailability (F30%): | 1 |
Blood-Brain-Barrier Penetration (BBB): | 0.029 | Plasma Protein Binding (PPB): | 100.01% |
Volume Distribution (VD): | 1.209 | Fu: | 0.77% |
CYP1A2-inhibitor: | 0.446 | CYP1A2-substrate: | 0.152 |
CYP2C19-inhibitor: | 0.793 | CYP2C19-substrate: | 0.047 |
CYP2C9-inhibitor: | 0.143 | CYP2C9-substrate: | 0.994 |
CYP2D6-inhibitor: | 0.98 | CYP2D6-substrate: | 0.41 |
CYP3A4-inhibitor: | 0.593 | CYP3A4-substrate: | 0.06 |
Clearance (CL): | 6.223 | Half-life (T1/2): | 0.561 |
hERG Blockers: | 0.263 | Human Hepatotoxicity (H-HT): | 0.148 |
Drug-inuced Liver Injury (DILI): | 0.162 | AMES Toxicity: | 0.015 |
Rat Oral Acute Toxicity: | 0.001 | Maximum Recommended Daily Dose: | 0.982 |
Skin Sensitization: | 0.968 | Carcinogencity: | 0.043 |
Eye Corrosion: | 0.011 | Eye Irritation: | 0.712 |
Respiratory Toxicity: | 0.489 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002894 | 0.848 | D0P1RL | 0.313 | ||||
ENC003312 | 0.546 | D0T9TJ | 0.310 | ||||
ENC001482 | 0.448 | D00MLW | 0.288 | ||||
ENC004818 | 0.406 | D07ILQ | 0.265 | ||||
ENC004641 | 0.395 | D0O1PH | 0.263 | ||||
ENC003972 | 0.390 | D0MM8N | 0.263 | ||||
ENC004669 | 0.390 | D00FGR | 0.256 | ||||
ENC003741 | 0.390 | D00STJ | 0.250 | ||||
ENC001340 | 0.389 | D0L5YV | 0.246 | ||||
ENC004673 | 0.386 | D00AOJ | 0.245 |